CCL2 and idiopathic pulmonary fibrosis: The authors concluded that senolytics may modulate inflammation and tissue remodeling in IPF, as evidenced by reduced MCP-1 and matrix remodeling proteins, while concurrently improving physical function in IPF, albeit not captured by conventional spirometry [46].